Answers are grounded in this paper and cite their sources.
Demonstrates that edaravone-loaded liposomes enhance cerebral blood flow and reduce brain infarct volume in ischemic stroke rats, suggesting an effective targeted neuroprotective therapy.
Aim: To construct an edaravone-encapsulated liposomes (EDV-LIPs) formulation against acute ischemic stroke. Methods: EDV-LIPs were prepared by the film dispersion method. The biosafety was evaluated both in vitro and in vivo by flow cytometry and the histological staining method. Biodistribution and therapeutic effect of EDV-LIPs against acute ischemic stroke was investigated by fluorescent imaging, the behavior test, laser speckle imaging and triphenyltetrazolium chloride staining. Results: The nanoliposomes had a long circulation time and could accumulate in the brain lesion region in ischemic stroke rats. EDV-LIPs show good biosafety. EDV-LIPs could restore more cerebral blood flow, reduce infarct volume and decrease neuronal apoptosis. Conclusion: EDV-LIPs provide an effective alternative for drug-targeted delivery against acute ischemic stroke.
No takes yet. Share an insight, caveat, or question.
Song et al. (2022) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: